Skip to main content
SpringerLink
Log in

Empagliflozin cost effective in Japan

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

  2. 2017 Japanese yen

Reference

  • Kaku K, et al. Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian population in the EMPA-REG OUTCOME Trial. Clinical Therapeutics : 24 Sep 2019. Available from: URL: http://doi.org/10.1016/j.clinthera.2019.07.016

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Empagliflozin cost effective in Japan. PharmacoEcon Outcomes News 839, 17 (2019). https://doi.org/10.1007/s40274-019-6298-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6298-3

Search

Navigation